ANABOLIC/CATABOLIC BALANCE IN SKELETAL MUSCLE OF MEN WITH PROSTATE CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们的目标是通过保护老年人的肌肉免受癌症和/或癌症治疗的影响，帮助患有癌症的老年人过上更健康、更有成效的生活。雄激素剥夺疗法(ADT)是前列腺癌的一种常见治疗方法，它极大地降低了血液中性激素睾酮的水平，以保护前列腺。ADT有助于延缓前列腺癌的进展或复发，但它也会导致肌肉的丧失。肌肉的这些变化令人担忧，因为它们会导致肌肉无力，并可能损害生活质量。此外，男性通常被诊断为前列腺癌的年龄(50-80岁)本身就与肌肉质量和力量的丧失有关。因此，ADT可能会导致老年男性早衰。尽管ADT被广泛使用，但人们对肌肉内解释肌肉萎缩和虚弱的生物学变化知之甚少。因此，我们将开始通过测量对肌肉维护重要的特定基因的变化来确定ADT的前3个月内肌肉生物学的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to help older adults with cancer live healthier, more productive lives by protecting their muscles from the effects of cancer and/or cancer treatment. Androgen-deprivation therapy (ADT), a common treatment for prostate cancer, dramatically reduces the levels of the sex hormone testosterone in the blood to protect the prostate. ADT is beneficial in delaying the progression or recurrence of prostate cancer, but it also causes the loss of muscle. These changes in muscle are troubling because they cause muscle weakness and can impair quality of life. Furthermore, the age at which men are typically diagnosed with prostate cancer (50 - 80 y) is in itself associated with a loss of muscle mass and strength. Thus, ADT may cause premature frailty in older men. Despite the widespread use of ADT, little is known about the biological changes within muscle that explain muscle atrophy and weakness. Therefore, we will begin to determine how muscle biology changes within the first 3 months of ADT by measuring changes in specific genes important to muscle maintenance.